

Galcanezumab for preventing migraine

Information for the public

Published: 18 November 2020

www.nice.org.uk

Galcanezumab (Emgality) is available on the NHS as a possible treatment for preventing migraine in adults who:

- have 4 or more migraine days a month
- have tried at least 3 other medicines and they have not worked.

You should only continue taking galcanezumab after 12 weeks of treatment if:

- episodic migraine (less than 15 headache days a month) reduced by at least 50%
- chronic migraine (15 headache days a month or more) reduced by at least 30%.

If you are not eligible for galcanezumab but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

This organisation can give you advice and support: [Migraine Trust](#), 0203 9510 150.

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-3912-1